Evidence map›Paper›PMID 39041564›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2024

[Predicting the 3-year tumor-specific survival in patients with T

Zezhen Zhou, Shaohui Deng, Ye Yan, Fan Zhang, Yichang Hao, Liyuan Ge, Hongxian Zhang, Guoliang Wang, Shudong Zhang

Abstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zezhen ZhouDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Shaohui DengDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Ye YanDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Fan ZhangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Yichang HaoDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Liyuan GeDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Hongxian ZhangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Guoliang WangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Shudong ZhangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo predict the 3-year cancer-specific survival (CSS) of patients with non-metastatic T

methodsA total of 336 patients with pathologically confirmed T

resultsBased on the Lasso regression screening results, the nomogram was constructed with five variables: tumor maximum diameter, histological grading, sarcomatoid differentiation, T

conclusionA nomogram model predicting the 3-year CSS of non-metastatic T

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNomogramsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedRetrospective StudiesROC CurveSurvival RateNomogramsPrognosisRenal cell carcinoma

Identifiers

PMID39041564
PMCPMC11284467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.